Watch and share this video on how Nirsevimab works by the American Society for Microbiology: https://youtu.be/f7isAsM2ydI?si=NdyRAWU0y292NtRH

To read the August 25, 2023 edition of the MMWR regarding infant RSV prevention. https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7234a4-H.pdf

Information about the Universal Vaccine Purchasing Program and the Massachusetts Vaccine Purchase Trust Fund: https://malegislature.gov/Laws/GeneralLaws/PartI/TitleXVI/Chapter111/Section24N#:~:text=The%20council%20shall%20recommend%20the%20as%20determined%20by%20the%20council.


Massachusetts Chapter of the American Academy of Pediatrics
FAQs About RSV Preventive Antibodies for Infants:

1. **What is Nirsevimab?** Nirsevimab is a monoclonal antibody product that is a passive immunization. While not technically a “vaccine” in a traditional sense (active immunization), it is being used in a manner similar to routine childhood vaccines and may be referred to as a vaccine by some entities. Nirsevimab confers long-lasting protection from RSV, with protection expected to last at least 5 months (about the length of a typical RSV season). Nirsevimab is part of the Vaccines for Children program.

2. **Should we call Nirsevimab a vaccine?** Legally, Nirsevimab is being included in most regulations regarding vaccines. Many clinicians are choosing terms “Nirsevimab immunization”, “RSV immunization”, or “RSV preventive antibodies” with patients. Just be consistent and factual.

3. **Who can administer Nirsevimab?** Any team member who is currently administering vaccines in your practice setting may administer Nirsevimab.

4. **What do I need to document for Nirsevimab administration?** Document just as you would a routine childhood vaccine to comply with federal law: Vaccine name and manufacturer, Lot number, date of administration, name/address/title of the administering HCP, the Immunization Information Statement (IIS) edition date from the lower righthand corner on the second page and the date the IIS was given to the caregiver. Federal law does not require a caregiver to sign a consent form in order to receive a vaccination; providing them with the appropriate VIS(s) and answering their questions is sufficient under federal law. Practices and hospitals may develop their own policies in addition to federally-compliant procedures.

5. **Is Nirsevimab/Beyfortus part of the MA Universal Child Vaccine Purchase Program?** Yes, it is. That means that any VFC provider in Massachusetts may order this product at no cost. It also means that non-VFC providers may not be ensured that private payers will cover the purchase cost of Nirsevimab and they will need to ask payers what their policy will be on payment outside VFC.

6. **Do you have any tools to help me figure out how many doses of Nirsevimab I should order?** Please get in touch with your Sanofi representative, who can provide you with a ordering tool to model how many doses to order. You may consider placing a small order initially as you gauge interest in the immunization among your patients as you will be able to place additional orders later in the season.

7. **How long can we keep Nirsevimab and will Sanofi accept product returns?** Nirsevimab has a long shelf life with expiration dates up to 18 months after distribution. At this time it is not assured that the product can be returned for refund or restitution. See MPDPH’s 2023 Guidelines for Compliance with Federal and State Vaccine Administration Requirements. You may be able to use product in up to two RSV seasons. Order carefully.

8. **Does reimbursement for Nirsevimab include counseling?** The current administration code is inadequate and does not take counseling, storage/handling, or reporting into consideration. The AAP is advocating for improved codes, as well as appropriate payment. As nirsevimab is the first product of its kind, the AAP recognizes that prompt and appropriate payment for nirsevimab will be challenging in the first year of implementation.

9. **How do I plan for use of paluzivimab (Synagis) this season as Nirsevimab (Beyfortus) is introduced?**
• If nirsevimab is administered, palivizumab should not be administered later that season.
• If palivizumab was administered initially for the season and <5 doses were administered, the infant should receive 1 dose of nirsevimab. No further palivizumab should be administered.
• If palivizumab was administered in season 1 and the child is eligible for RSV prophylaxis in season 2, the child should receive nirsevimab in season 2, if available. If nirsevimab is not available, palivizumab should be administered as previously recommended.

10. **How do I report suspected adverse reactions to Nirsevimab?** Report side effects that happen after getting nirsevimab (with NO coadministered vaccines) to the MedWatch website or by calling 1-800-FDA-1088. Report side effects that happen after getting nirsevimab WITH coadministered vaccines (the same day) to the VAERS website or by calling 1-800-822-7967.

11. **If an infant has been diagnosed with RSV this season, should they still receive nirsevimab?** Unlike palivizumab (Synagis), Nirsevimab recommendations are the same regardless of prior RSV infection or RSV-associated hospitalization.

---

**A Few Words About Maternal RSV Vaccine:**

1. **What does the American College of Obstetricians say about the maternal RSV vaccine?** “ACOG unequivocally supports ACIP’s recommendation for the use of the maternal RSV vaccine in pregnancy during 32 through 36 weeks gestation using seasonal administration. The national and global burden of RSV disease demonstrates how critical it is to prevent this virus in infants. ACOG believes the maternal RSV vaccine is efficacious and it is necessary that parents have this option to protect their newborns from RSV after birth. ACOG is currently making updates to its clinical guidance that will be released in the coming days.”

2. **If an infant’s mother has received maternal RSV vaccine, should the infant receive nirsevimab?** The CDC does not recommend nirsevimab for most infants born to a mother who received maternal RSV vaccine, except for infants where less than 14 days have elapsed between vaccination and birth.

3. **Are there any videos on how maternal RSV vaccine works?** The ACIP recommendation for maternal RSV vaccine (ABYSVO) is new (9/22/23) so fewer scientists have made videos on this so far, but here are two overviews of the vaccine. https://www.contagionlive.com/view/the-changing-rsv-prevention-landscape (mostly after 3:00) and https://www.contagionlive.com/view/fda-advisory-committee-affirms-safety-and-efficacy-of-pfizer-rsvpref-vaccine (after 2:00).

4. **Will the CDC provide a Vaccine Information Sheet (VIS) for Nirsevimab?** https://www.cdc.gov/vaccines/vpd/rsv/downloads/Immunization-Information-Statement.pdf

CDC’s Nirsevimab “Immunization Information Sheet” can be found at: https://www.cdc.gov/vaccines/vpd/rsv/downloads/Immunization-Information-Statement.pdf
Nirsevimab CPT Codes for Product Billing


- Report codes 90380–90381 based on the dose administered: 0.5mL or 1.0 mL.
- 90380: Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL (50 mg) dosage, for intramuscular use
- 90381: Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL (100 mg) dosage, for intramuscular use

Follow state specifications for reporting the immunization when the immunoglobulin product is provided through the Vaccines for Children program. For example, report 90380 SL to indicate state-supplied product. From https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-coding--payment/

Administration CPT Codes and ICD-10 Codes

Administration Code
- Report the administration of nirsevimab with code 96372 (injection, subcutaneous or intramuscular). Do not report immunization administration codes 90461–90462 or 90471–90472 for the injection of nirsevimab, as these codes are limited to the administration of vaccine and toxoid products. See examples of reporting administration of nirsevimab along with other services in the coding vignettes below.

Diagnosis Codes
- Administration of nirsevimab is not reported with Z23 Encounter for immunization. Z23 is specific to immunization related to vaccines. While nirsevimab is categorized as a monoclonal antibody by CPT, ICD10 CM’s index guides us to code Z29.11 Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV). Using the appropriate diagnosis code is not only important for billing and claims payment, but it is also necessary for data collection and quality metrics.

Coding Vignettes

Outpatient Setting:

Vignette 1: A 6-month-old previously healthy patient presents with a 2-day history of cough and runny nose and today started with a fever of 100.1, and after an exam is diagnosed with a URI. Mother would like to know what else she could do to protect her baby from getting sick since the fall season is starting. Mother is counseled for 20 minutes about the recommendations for flu, COVID vaccines, and nirsevimab. All her questions were answered, and we will discuss more when the baby returns next week for a well-child check.
CPT Codes Used:

99213 Office or other outpatient visit for the E/M of an established patient, requiring straightforward medical decision-making.

99401 Preventive medicine counseling provided to an individual; approximately 15 minutes

**Coding Tips:** Modifier 25 is required to report codes 99213 and 99401 together.

Preventive medicine counseling codes are **not** reportable with well visit codes 99381-99385 and 99391-99395

**Vignette 2:** A 2-month-old established patient born prior to the start of the RSV season is seen in the office for a well exam. The patient is up to date with vaccines and will be receiving the recommended 2-month vaccines. In addition, the provider counsels the mother about nirsevimab. All of mother’s questions were answered, and she would like to proceed with the recommendations.

CPT Codes used:

99391 Periodic comprehensive preventive medicine reevaluation and management of an established patient; infant (age younger than 1 year)

Appropriate Coding for Tdap, IPV, PCV, Hib, Rotavirus, Hep B combination vaccines administered

90380 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for IM use

Vaccine/Monoclonal Antibody Administration:

90460 IM through 18 yrs, any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered = 3 units OR

90461 IM administration through 18 yrs, any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered = 4 units AND

96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular = 1 unit

**Vignette 3:** A 7-month-old established patient presents for a scheduled nirsevimab injection. Counseling was provided by the physician at the well-child visit 2 weeks ago, Mother had additional questions that were answered by the RN. Mother agrees to proceed with the administration of nirsevimab.

CPT codes used:

90381 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for IM use

96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); SC or IM

**Coding Tip:** Additional counseling provided by RN and subsequent administration of nirsevimab does not support reporting an additional E/M code such as 99211. To report any E/M, a condition
must be evaluated and managed; for coding purposes, counseling does not equate to the management of a condition.

Vignette 4: An 18-month-old established patient with a history of severe immune compromise presents for a well-child visit. A preventive service is provided, including age-appropriate developmental screening. The physician also counsels on RSV prevention and discusses the risks and benefits of receiving nirsevimab. All of the family’s questions are answered and documented. The patient receives nirsevimab 200 mg (2 separate injections of 100 mg each) via intramuscular injection.

CPT codes:
99392 Periodic comprehensive preventive medicine reevaluation and management of an established patient; early childhood (age 1 through 4 years)
96110 Developmental screening (eg, developmental milestone survey, speech and language delay screen), with scoring and documentation, per standardized instrument
90381 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for IM use = 2 units
96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular = 2 units

Nursery Setting:
Vignette: A 2-day-old patient weighing 3 kg was born during the RSV season. Counseling on RSV prevention was provided by the hospitalist, including the risks and benefits of receiving nirsevimab. All of the family's questions are answered and documented, and the newborn receives nirsevimab 0.5 mL prior to hospital discharge

CPT Codes Used:
90380 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for IM use
96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular = 1 unit

Coding Tips: Inpatient counseling for nirsevimab and any other medications or vaccines is bundled into any E/M provided on that date of service. Since the vignette shows no other billable services, a claim should not be filed by the hospitalist for counseling for nirsevimab.
Practical Considerations of Nirsevimab Timing

Here are some tools that help you identify the time to administer Nirsevimab in your practice:

**Month of birth**  **Recommended timing of nirsevimab immunization**
October–March  Within 1 week of birth
April–September  Beginning in October, for example at a 2, 4, or 6 month well child visit

### Looking Back and Forward to Infants Born in 2023 and 2024

<table>
<thead>
<tr>
<th>Month of Birth</th>
<th>Eligible this season?</th>
<th>When Eligible?</th>
<th>Closest WCC or vax visit?</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 2023</td>
<td>No, unless high risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>February 2023</td>
<td>Maybe. Some will be 8 months after introduction</td>
<td>October 2023</td>
<td>Vax visit or 9 month WCC in 11/23</td>
</tr>
<tr>
<td>March 2023</td>
<td>Yes</td>
<td>October 2023</td>
<td>Vax visit</td>
</tr>
<tr>
<td>April 2023</td>
<td>Yes</td>
<td>October 2023</td>
<td>6 month WCC in 10/23 or vax visit</td>
</tr>
<tr>
<td>May 2023</td>
<td>Yes</td>
<td>October 2023</td>
<td>6 month WCC in 11/23 or vax visit</td>
</tr>
<tr>
<td>June 2023</td>
<td>Yes</td>
<td>October 2023</td>
<td>4 month WCC in 10/23 or vax visit</td>
</tr>
<tr>
<td>July 2023</td>
<td>Yes</td>
<td>October 2023</td>
<td>4 month WCC in 11/23 or vax visit</td>
</tr>
<tr>
<td>August 2023</td>
<td>Yes</td>
<td>October 2023</td>
<td>2 month WCC in 10/23 or vax visit</td>
</tr>
<tr>
<td>September 2023</td>
<td>Yes</td>
<td>October 2023</td>
<td>1 month WCC in 10/23 or vax visit</td>
</tr>
<tr>
<td>October 2023</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
<tr>
<td>November 2023</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
<tr>
<td>December 2023</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
<tr>
<td>January 2024</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
<tr>
<td>February 2024</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
<tr>
<td>March 2024</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
<tr>
<td>April 2024</td>
<td>Yes</td>
<td>October 2024</td>
<td>6 month WCC in 10/24 or vax visit</td>
</tr>
<tr>
<td>May 2024</td>
<td>Yes</td>
<td>October 2024</td>
<td>6 month WCC in 11/24 or vax visit</td>
</tr>
<tr>
<td>June 2024</td>
<td>Yes</td>
<td>October 2024</td>
<td>4 month WCC in 10/24 or vax visit</td>
</tr>
<tr>
<td>July 2024</td>
<td>Yes</td>
<td>October 2024</td>
<td>4 month WCC in 11/24 or vax visit</td>
</tr>
<tr>
<td>August 2024</td>
<td>Yes</td>
<td>October 2024</td>
<td>2 month WCC in 10/24 or vax visit</td>
</tr>
<tr>
<td>September 2024</td>
<td>Yes</td>
<td>October 2024</td>
<td>1 month WCC in 10/24 or vax visit</td>
</tr>
<tr>
<td>October 2024</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
<tr>
<td>November 2024</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
<tr>
<td>December 2024</td>
<td>Yes</td>
<td>At birth or soon after</td>
<td>In first 2-4 weeks if possible</td>
</tr>
</tbody>
</table>
Nirsevimab Scheduling Questions:

I have a healthy patient who was 7 months old in October. They present to the clinic in November, at 8 months of age. Can they receive nirsevimab at this visit? From AAP.org: No. CDC recommends that only those healthy infants younger than 8 months of age at the time of administration receive nirsevimab.

Should I administer nirsevimab to an infant who is born at the very end of the RSV season? From AAP.org: Yes. Optimal timing for administration is within 1 week after birth during the RSV season. Administering nirsevimab through the end of the season is important because the risk of severe disease is highest during the first few months of life.

What does "shortly before or during" the RSV season mean? When should I start administering nirsevimab? From AAP.org: In most of the continental US, “shortly before or during the season” means that administration of nirsevimab should begin on October 1 and conclude on March 31. In tropical climates (southern Florida, Hawaii, Guam, Puerto Rico, US Virgin Islands and US-affiliated Pacific Islands) and Alaska, RSV circulation patterns may differ. Because timing of the onset, peak and decline of RSV activity may vary, providers can adjust administration schedules based on local RSV activity in the community. The Centers for Disease Control and Prevention (CDC) monitors RSV activity in the United States in collaboration with state and county health departments and commercial and clinical laboratories. These data are available from the National Respiratory and Enteric Virus Surveillance System. Information about local epidemiology can be determined by contacting your local, state, tribal, or territorial health department or other local health authority. Optimal timing for nirsevimab administration is shortly before the RSV season begins, however, it may be given to eligible infants and toddlers who have not yet received a dose at any time during the season.

Per CDC, healthcare providers may choose to give nirsevimab before the start of RSV season if they feel that the child may not return for a visit when nirsevimab would be recommended. For example, a clinician may choose to give nirsevimab to an infant who presented for care in September who has not yet received a dose of nirsevimab and may be unlikely to return for a visit in October or November. Nirsevimab has been shown to protect against severe RSV disease for at least 5 months, and the ideal timing of administration may differ depending on the clinical situation.
Nirsevimab Administration
Visual Guide

Is it October 1 through March 31, or have regional experts or health authorities recommended nirsevimab administration currently?
- Yes
- No

Is the patient < 8 months of age today?
- Yes
- No or Unknown

Did the mother of this patient receive the RSV vaccine while pregnant?
- Yes
- No

Was the infant born within 14 days of maternal RSV vaccine administration?
- Yes
- No

Has the patient received a previous dose of nirsevimab in the current RSV season (eg. in the newborn nursery)?
- Yes
- No

Has the patient received 1 or more doses of palivizumab in the current RSV season?
- Yes
- No

Has 30 days elapsed since the last dose?
- Yes
- No

What is the patient’s current weight (today)?
- < 5 kg
- ≥ 5 kg

Nirsevimab 50 mg/0.5 mL
Nirsevimab 100 mg/mL

Nirsevimab 200 mg

Recommended
Not Recommended

a. Children 8 through 19 months of age who are recommended to receive nirsevimab when entering their second RSV season because of increased risk of severe disease.
- Children with chronic lung disease of prematurity who required medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season.
- Children who are severely immunocompromised.
- Children with cystic fibrosis who have manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest imaging that persist when stable) or have weight-for-length that is <10th percentile.
- American Indian and Alaska Native children (note that this is a new group for whom second-season prophylaxis is recommended in contrast to the current palivizumab recommendations).

b. Nirsevimab can be considered when, per the clinical judgement of the healthcare provider, the potential incremental benefit of administration is warranted, including but not limited to the following rare circumstances:
- Infants born to pregnant people who may not mount an adequate immune response to vaccination or have conditions associated with reduced transplacental antibody transfer.
- Infants who have undergone cardiopulmonary bypass or extracorporeal membrane oxygenation leading to loss of maternal antibodies.
- Infants with substantial increased risk for severe RSV disease (eg, hemodynamically significant congenital heart disease, intensive care admission, and requiring oxygen at discharge).
At the time of administration, affirm the 7 rights to reduce errors:

1. Right patient
2. Right time (age, in RSV season)
3. Right immunization (correct medication)
4. The right dosage (based on weight)
5. The right route, needle length, and technique
6. Right site

### Intramuscular (IM) injection

*Use a 22–25 gauge needle. Choose the injection site and needle length that is appropriate to the person's age and body mass.*

<table>
<thead>
<tr>
<th>Age</th>
<th>Needle length</th>
<th>Injection site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborns (1st 28 days)</td>
<td>⅝”c</td>
<td>Anterolateral thigh muscle</td>
</tr>
<tr>
<td>Infants (1–12 months)</td>
<td>1”</td>
<td>Anterolateral thigh muscle</td>
</tr>
<tr>
<td>Toddlers (1–2 years)</td>
<td>1–1¼”</td>
<td>Anterolateral thigh muscle e</td>
</tr>
<tr>
<td></td>
<td>¾”d–1”</td>
<td>Deltoid muscle of arm</td>
</tr>
</tbody>
</table>

7. The right documentation

c. If skin is stretched tightly and subcutaneous tissues are not bunched.
d. Alternate needle lengths may be used if the skin is stretched tightly and subcutaneous tissues are not bunched, as follows: a) a ⅝” needle in toddlers, children, and patients weighing less than 150 lbs (less than 60 kg) for IM injection in the deltoid muscle only, or b) a 1” needle for administration in the thigh muscle for adults of any weight.
e. Preferred site

**NOTE:** Always refer to the package insert included with each biologic for complete vaccine administration information. CDC's Advisory Committee on Immunization Practices (ACIP) recommendations for the particular vaccine should be reviewed as well. Access the ACIP recommendations at [www.immunize.org/acip](http://www.immunize.org/acip).